Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IARS1 | P41252 | 6/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634255 | 0.91 | IARS1 (0.57) | IARS1ALOX15CYP3A4TSHRALOX12 | |
| SCHEMBL3665421 | 0.88 | IARS1 (0.62) | IARS1ALOX15GAACYP3A4TSHR | |
| SCHEMBL3665669 | 0.79 | IARS1 (0.56) | IARS1ALOX15GAACYP3A4TSHR | |
| SCHEMBL3667396 | 0.79 | IARS1 (0.62) | IARS1ALOX15CYP3A4TSHRTRPV1 | |
| SCHEMBL3665648 | 0.78 | AAK1 (0.59) | IARS1ALOX15GAACYP3A4RAB9A | |
| SCHEMBL3635282 | 0.73 | GAA (0.46) | ALOX15GAACYP3A4TSHRKDM4E | |
| SCHEMBL14264743 | 0.71 | LMNA (0.58) | TSHR | |
| SCHEMBL31171264 | 0.71 | IARS1 (0.67) | IARS1ALOX15GAATSHRALOX12 | |
| SCHEMBL27535357 | 0.71 | ALOX15 (0.56) | IARS1ALOX15GAACYP3A4TSHR | |
| SCHEMBL3445149 | 0.70 | ALOX15 (0.49) | ALOX15GAACYP3A4TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | claimed |
| EP-2131854-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | Aeterna Zentaris Gmbh (DE) | 2009-12-16 | — | — | EP | claimed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | claimed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | claimed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | claimed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2131854-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | Aeterna Zentaris Gmbh (DE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | IARS1 2049/4885ALOX15 1059/4885GAA 4227/4885 |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | LHCGR, GNRHR, FSHR | IARS1 479/4885ALOX15 2834/4885GAA 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.